U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07374614) titled 'Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib' on Jan. 16.
Brief Summary: This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy. The results are expected to provide real-world evidence to inform clinical decision-making for this heavily pretreated patient population.
Study Start Date: Jan. 31
Study Type: OBSERVATIONAL
Condition:
Non-Small Cell Lung Cancer
ALK
Iruplinalkib
Lorlatinib
Real-world Study
Observational Study
Interventio...